Matinas BioPharma Holdings, Inc. / Fundamentals
Income statement
- Net revenue
€820.54K - Cost of goods sold
€105.77K - Gross profit
-€105.77K - SG&A expenses
€6.40M - R&D expenses
€4.01M - EBITDA
-€9.99M - D&A
€418.80K - EBIT
-€10.41M - Interest expenses
€0.00 - EBT
-€16.79M - Tax expenses
-€68.24K - Net income
-€16.73M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€6.75M - Changes in working capital
-€709.66K - Operating cash flow
-€9.41M - Capex
€0.00 - Other investing cash flow
€6.77M - Net investing cash flow
€8.65M - Total cash dividends paid
€0.00 - Issuance of common stock
€2.74M - Debt repayment
-€3.41K - Other financing cash flow
€1.38M - Net financing cash flow
€2.73M - Foreign exchange effects
€0.00 - Net change in cash
€1.97M - Cash at end of period
€5.78M - Free cash flow
-€9.41M
Balance sheet
- Cash and cash equivalents
€5.57M - Cash and short-term investments
€5.57M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€633.74K - Total current assets
€6.20M - Property, plant & equipment
€1.39M - Goodwill
€0.00 - Intangible assets
€1.93M - Long-term investments
€170.59K - Other non-current assets
€59.71K - Total non-current assets
€3.54M - Total assets
€9.74M - Accounts payable
€142.44K - Short-term debt
€701.13K - Other current liabilities
€678.10K - Total current liabilities
€1.52M - Long-term debt
€1.46M - Deferred tax liabilities
€219.21K - Other non-current liabilities
€0.00 - Total non-current liabilities
€1.68M - Total liabilities
€3.20M - Common stock
€852.95 - Retained earnings
-€176.33M - Other equity
€0.00 - Total equity
€6.55M - Total liabilities and shareholders' equity
€9.74M
Company information
- Market capitalization
€3.99M - Employees
3 - Enterprise Value
€1.08M
Company ratios
- Gross margin
-
-12.9% Much better than peer group: -219.1% - EBITDA margin
-
-1,217.4% Much better than peer group: -1,794.7% - EBIT margin
-
-1,268.4% Much better than peer group: -1,885.8% - EBT margin
-
-2,046.7% Much worse than peer group: -566.6% - Net margin
-
-2,038.4% Much worse than peer group: -1,872.6% - ROE
-
-255.5% Much worse than peer group: -76.1% - ROA
-
-171.6% Much worse than peer group: -50.1% - Asset turnover
-
8.4% Much better than peer group: -810.9% - FCF margin
-
-1,147.4% Much better than peer group: -1,252.3% - FCF yield
-235.8% - Efficiency ratio
1,317.4% - Net sales per employee
-
€273.51K - Net income per employee
-
-€5.58M